Stefan Weber, CEO of Newron Pharmaceuticals provides a company overview and the focus on Rett Syndrome. Newron is focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system.
Xadago (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s Partner Zambon. Newron also has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome. This discussion focuses on Rett syndrome.